CompletedPhase 2NCT00841789

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

Studying Kawasaki disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Michael Portman
Principal Investigator
Michael A Portman, MD
Seattle Children's Hospital
Intervention
Etanercept(drug)
Enrollment
205 enrolled
Eligibility
20 years · All sexes
Timeline
20092018

Study locations (8)

Collaborators

Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00841789 on ClinicalTrials.gov

Other trials for Kawasaki disease

Additional recruiting or active studies for the same condition.

See all trials for Kawasaki disease

← Back to all trials